EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits

Amritha T M Seetharaman, Caroline E Owens, Rajashekhar Gangaraju iD

Journal of Ocular Pharmacology and Therapeutics · 2024

DOI: 10.1089/jop.2024.0111 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2024. Verfasst von Amritha T M Seetharaman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Acetates, Cyclopropanes, Leukotriene Antagonists, Quinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Montelukast, a Food and Drug Administration-approved drug for asthma and allergic rhinitis modulates leukotriene (LT) receptors and serves as a critical anti-inflammatory agent. Recent research suggests that the LT signaling pathway targeted by montelukast has broader implications for diseases such as fibrosis, cardiovascular diseases, cancer, cerebrovascular disease, and immune defense. This expanded understanding highlights montelukast's potential for repurposing in conditions involving aberrant stress mechanisms, including ocular diseases marked by inflammation, oxidative stress, ER stress, and apoptosis, among several others. This review delves into montelukast's therapeutic mechanisms across various diseases, draws parallels to ocular conditions, and examines clinical trials and associated adverse effects to underscore the unmet need for cysteinyl LT receptor antagonism by montelukast as an effective therapy for visual deficits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetatesCyclopropanesLeukotriene AntagonistsQuinolinesSulfidesAnimalsHumansReceptors, LeukotrieneVision Disorders

Stichwörter der Autor:innen

CysLTR1autophagydiabetesendothelial dysfunctioninflammationocular

Substanzen

AcetatesCyclopropanesLeukotriene AntagonistsmontelukastQuinolinesReceptors, LeukotrieneSulfides

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Department of Ophthalmology, Anatomy & Neurobiology, Neuroscience Institute, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

ORCID-Profile: Rajashekhar Gangaraju

Förderung

  • NEI NIH HHS

Zitieren

APA

Seetharaman, A. T. M., Owens, C. E., & Gangaraju, R. (2024). Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2024.0111

Vancouver

Seetharaman ATM, Owens CE, Gangaraju R. Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits. Journal of Ocular Pharmacology and Therapeutics. 2024. doi:10.1089/jop.2024.0111

BibTeX
@article{Seetharaman2024,
  author = {Seetharaman, Amritha T M and Owens, Caroline E and Gangaraju, Rajashekhar},
  title = {Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits},
  journal = {Journal of Ocular Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.1089/jop.2024.0111}
}
Kostenlos starten →